Ocean Biomedical, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
10-Q: Ocean Biomedical Reports Q1 2025 Results Amidst Going Concern Doubts and Nasdaq Delisting Notice
Ocean Biomedical's Q1 2025 report reveals a net loss, a working capital deficiency, and substantial doubt about its ability to continue as a going concern, alongside a Nasdaq delisting notice.
OTC.Pink
Ocean Biomedical's Q3 2024 report reveals ongoing operating losses and a working capital deficiency, alongside efforts to secure additional funding and address debt obligations.
OTC.Pink
10-Q: Ocean Biomedical Reports Q2 2024 Results Amidst Financial Challenges and Restructuring Efforts
Ocean Biomedical's Q2 2024 report reveals ongoing financial difficulties, including a working capital deficiency and significant net losses, alongside efforts to secure additional funding and restructure debt.
OTC.Pink
Ocean Biomedical reported a net income of $13 million for Q1 2024, a significant shift from a net loss of $72.1 million in the same period last year, primarily due to gains from changes in fair value of financial instruments.
OTC.Pink
Ocean Biomedical's Q3 2023 report reveals a significant net loss and restatement of prior financials due to accounting errors related to a backstop agreement.
OTC.Pink
Ocean Biomedical has amended its Q2 2023 report to correct accounting errors related to a backstop agreement and other financial items.
OTC.Pink
Ocean Biomedical has restated its first quarter 2023 financial statements due to an error in the accounting treatment of a backstop agreement, reclassifying a prepayment and adjusting liabilities.